Telomir Pharmaceuticals, Inc. Interest Expense Nonoperating
Telomir Pharmaceuticals, Inc. (TELO) reported Interest Expense Nonoperating of $3.03 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $3.03K, a 125.63% increase year-over-year.
- Telomir Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $1.25K, a 2628.26% increase year-over-year.
- Telomir Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Telomir Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2025-06-30 was $1.34K.
- Telomir Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2024 was $4.34M, a 164.05% increase from fiscal 2023.
- Telomir Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2023 was $1.64M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.03K 10-Q · filed 2026-08-13 | $4.28K 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $1.25K 10-Q · filed 2026-05-14 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.34K derived: sum of 2 quarters · filed 2026-08-13 | $1.39K 10-Q · filed 2025-11-10 | $1.39K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.34K 10-Q · filed 2026-08-13 | $1.39K 10-Q · filed 2026-08-13 | $1.39K derived: sum of 3 quarters · filed 2026-08-13 | $1.39K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $46.00 10-Q · filed 2026-05-14 | $45.00 derived: sum of 2 quarters · filed 2026-05-14 | $46.00 derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $4.34M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.34M 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $4.34M 10-Q · filed 2025-08-14 | |||
| 2023-12-31 | $761.82K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-04 | $1.52M derived: sum of 2 quarters · filed 2025-02-04 | $1.64M derived: sum of 3 quarters · filed 2025-02-04 | $1.64M 10-K · filed 2025-02-04 |
| 2023-09-30 | $757.17K 10-Q · filed 2024-11-12 | $881.23K derived: sum of 2 quarters · filed 2024-11-12 | $881.23K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $124.05K 10-Q · filed 2024-08-13 | $124.05K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |